Henry Schein (NASDAQ:HSIC – Get Free Report) had its price target boosted by equities researchers at Morgan Stanley from $64.00 to $68.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has an “underweight” rating on the stock. Morgan Stanley‘s price target would suggest a potential downside of 20.64% from the company’s previous close.
A number of other analysts also recently issued reports on HSIC. Wall Street Zen raised Henry Schein from a “hold” rating to a “buy” rating in a research report on Monday, August 17th. Barclays reiterated an “overweight” rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Stifel Nicolaus set a $95.00 price target on Henry Schein in a research report on Wednesday, August 5th. Citigroup restated a “buy” rating and issued a $112.00 price target (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Barrington Research set a $104.00 price target on Henry Schein in a research note on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $93.86.
Get Our Latest Research Report on HSIC
Henry Schein Stock Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.20. Henry Schein had a net margin of 3.07% and a return on equity of 16.39%. The firm had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the previous year, the business earned $1.38 EPS. The company’s revenue was up 4.0% compared to the same quarter last year. Research analysts forecast that Henry Schein will post 5.40 EPS for the current fiscal year.
Institutional Investors Weigh In On Henry Schein
Hedge funds have recently added to or reduced their stakes in the business. Southpoint Capital Advisors LP boosted its holdings in shares of Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after purchasing an additional 700,000 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Henry Schein in the 2nd quarter valued at $42,261,000. Defilade Capital Management L.P. raised its holdings in shares of Henry Schein by 94.8% during the 1st quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock worth $45,992,000 after buying an additional 303,615 shares in the last quarter. Bank of Nova Scotia raised its holdings in shares of Henry Schein by 1,263.1% during the 1st quarter. Bank of Nova Scotia now owns 116,808 shares of the company’s stock worth $8,609,000 after buying an additional 108,239 shares in the last quarter. Finally, Banyan Capital Management Inc. acquired a new position in shares of Henry Schein during the 3rd quarter worth $8,023,000. Institutional investors and hedge funds own 96.62% of the company’s stock.
Key Stories Impacting Henry Schein
Here are a few of the latest stories about HSIC:
- Positive Sentiment: Henry Schein launched BRIDGE Health Network, a strategic development that could support its healthcare offerings. A related article questions whether the estimated 16% undervaluation is compelling, so the valuation case is not settled. Henry Schein (HSIC) Launches BRIDGE Health Network, Is The 16% Undervaluation Convincing?
- Neutral Sentiment: BMO Capital maintained a Hold rating and its $85 price target. The analyst cited improving dental demand as supportive of recovery, while caution kept the target unchanged. Henry Schein: Improving Dental Demand Supports Recovery, but Caution Keeps the $85 Price Target Unchanged
- Negative Sentiment: Morgan Stanley raised its price target to $68 from $64 but retained an Underweight rating, signaling that the firm still sees meaningful downside relative to the then-current share price. Morgan Stanley rating and price-target information
About Henry Schein
Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.
Further Reading
- Five stocks we like better than Henry Schein
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
